Halil Komek1, Canan Can2, Ugur Yilmaz3, Serdar Altindag2. 1. Department of Nuclear Medicine, Saglik Bilimleri University Diyarbakir Gazi Yasargil Training and Research Hospital, Kayapınar, Diyarbakir, Turkey. halilkomek@gmail.com. 2. Department of Nuclear Medicine, Saglik Bilimleri University Diyarbakir Gazi Yasargil Training and Research Hospital, Kayapınar, Diyarbakir, Turkey. 3. Department of Radiation Oncology, Saglik Bilimleri University Diyarbakir Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey.
Abstract
OBJECTIVE: To determine the association of 68 Ga-PSMA-I&T PET/CT SUV parameters with survival outcome in advanced prostate cancer patients. METHODS: A total of 148 consecutive patients mean age: 69.3 ± 7.8 years with advanced prostate cancer who underwent 68 Ga-PSMA-I&T PET/CT were included in this retrospective study. Data on previous treatments, serum PSA levels (ng/mL), 68 Ga-PSMA-I&T PET/CT findings metastases as well as survival data were recorded. RESULTS: Multivariate regression analysis revealed that Level 1 LN SUV/Liver SUV ratios > 2.17 (OR 4.262; 95% CI 1.104-16.453, p = 0.035), bone SUV > 10.7(OR 23.650; 95% CI 4.056-137.888, p < 0.001), bone SUV/spleen SUV ratio > 1.842 (OR 25.324; 95% CI 4.204-152.552, p < 0.001), highest SUVmax/liver SUV ratio > 2.32 (OR 19.309; 95% CI 1.730-209.552, p = 0.016) and highest SUVmax/spleen SUV ratio > 1.842 (OR 22.354; 95% CI 2.637-189.493, p = 0.004) were significant in the determination of increased mortality risk in advanced prostate cancer patients. CONCLUSION: Our findings, for the first time in literature, provided evidence on potential utility of tracer uptake (SUV) cut-off values on 68 Ga-PSMA PET/CT in identification of the survival outcome of patients with metastatic disease and thereby in assisting in the selection of individualized therapeutic strategies tailored to the expected prognosis.
OBJECTIVE: To determine the association of 68 Ga-PSMA-I&T PET/CT SUV parameters with survival outcome in advanced prostate cancerpatients. METHODS: A total of 148 consecutive patients mean age: 69.3 ± 7.8 years with advanced prostate cancer who underwent 68 Ga-PSMA-I&T PET/CT were included in this retrospective study. Data on previous treatments, serum PSA levels (ng/mL), 68 Ga-PSMA-I&T PET/CT findings metastases as well as survival data were recorded. RESULTS: Multivariate regression analysis revealed that Level 1 LN SUV/Liver SUV ratios > 2.17 (OR 4.262; 95% CI 1.104-16.453, p = 0.035), bone SUV > 10.7(OR 23.650; 95% CI 4.056-137.888, p < 0.001), bone SUV/spleen SUV ratio > 1.842 (OR 25.324; 95% CI 4.204-152.552, p < 0.001), highest SUVmax/liver SUV ratio > 2.32 (OR 19.309; 95% CI 1.730-209.552, p = 0.016) and highest SUVmax/spleen SUV ratio > 1.842 (OR 22.354; 95% CI 2.637-189.493, p = 0.004) were significant in the determination of increased mortality risk in advanced prostate cancerpatients. CONCLUSION: Our findings, for the first time in literature, provided evidence on potential utility of tracer uptake (SUV) cut-off values on 68 Ga-PSMA PET/CT in identification of the survival outcome of patients with metastatic disease and thereby in assisting in the selection of individualized therapeutic strategies tailored to the expected prognosis.
Authors: Panagiotis J Vlachostergios; Muhammad Junaid Niaz; Michael Sun; Seyed Ali Mosallaie; Charlene Thomas; Paul J Christos; Joseph R Osborne; Ana M Molina; David M Nanus; Neil H Bander; Scott T Tagawa Journal: Front Oncol Date: 2021-02-18 Impact factor: 6.244
Authors: Roberto Fedrigo; Dan J Kadrmas; Patricia E Edem; Lauren Fougner; Ivan S Klyuzhin; M Peter Petric; François Bénard; Arman Rahmim; Carlos Uribe Journal: EJNMMI Phys Date: 2022-01-15
Authors: Stefan A Koerber; Johannes Boesch; Clemens Kratochwil; Ingmar Schlampp; Jonas Ristau; Erik Winter; Stefanie Zschaebitz; Luisa Hofer; Klaus Herfarth; Klaus Kopka; Tim Holland-Letz; Dirk Jaeger; Markus Hohenfellner; Uwe Haberkorn; Juergen Debus; Frederik L Giesel Journal: Cancers (Basel) Date: 2021-03-25 Impact factor: 6.639